title: Tamoxifen inhibits lipoprotein activity: in vivo and in vitro studies.
abstract: Tamoxifen, a nonsteroidal antiestrogenic antitumor agent, has weak estrogen-like effects on lipid metabolism, however, the mechanism remains unknown. We previously reported that tamoxifen decreases the activity of lipoprotein lipase (LPL), a key enzyme in triglyceride metabolism, in patients with breast cancer. This study evaluated the effect of tamoxifen on LPL activity in vitro and in vivo. In experiment 1, total cholesterol, triglyceride, adipose tissue weight, and LPL activity of post-heparin plasma were measured in ovariectomized female rats with and without tamoxifen treatment. In experiment 2, purified very-low-density lipoprotein (VLDL) and purified LPL were incubated with and without tamoxifen or estrogen, and the triglycerides in VLDL were measured using an enzymatic method. In experiment 1, total cholesterol and adipose tissue weight decreased significantly in tamoxifen-treated rats (p < 0.001 and p < 0.01, respectively). Triglyceride measurements were not significantly different between the two groups, however, the LPL activity was lower in tamoxifen-treated rats (p < 0.005). In experiment 2, triglycerides in VLDL were significantly higher after VLDL and LPL were incubated with tamoxifen and estrogen (p < 0.005). We concluded that tamoxifen inhibits the hydrolytic activity of LPL in vivo and in vitro. This mechanism may explain the elevated serum triglyceride levels in some patients treated with tamoxifen.
authors.affiliation: Department of Surgery and Endocrinology and Metabolism, Omiya Medical Center, Jichi Medical School, Saitama, Japan. yahozumi@omiaya.jichi.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Hozumi
authors.forename: M
authors.initials: M
authors.lastname: Kawano
authors.forename: Y
authors.initials: Y
authors.lastname: Hakamata
authors.forename: M
authors.initials: M
authors.lastname: Miyata
authors.forename: V C
authors.initials: VC
authors.lastname: Jordan
mesh_terms: D000818:Animals; D004791:Enzyme Inhibitors / Q000494:pharmacology; D020847:Estrogen Receptor Modulators / Q000494:pharmacology*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors* / Q000097:blood; D008074:Lipoproteins / Q000097:blood / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000097:blood / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013629:Tamoxifen / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D013629:Tamoxifen; D008071:Lipoprotein Lipase